[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@avidresearch Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::82162291.png) @avidresearch avidresearch

avidresearch posts on X about $wve, $capr, $srpt, $cytk the most. They currently have XXXXXX followers and 1611 posts still getting attention that total XXXXX engagements in the last XX hours.

### Engagements: XXXXX [#](/creator/twitter::82162291/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::82162291/c:line/m:interactions.svg)

- X Week XXXXXX +101%
- X Month XXXXXXX -XX%
- X Months XXXXXXXXX +48%
- X Year XXXXXXXXX +101%

### Mentions: XX [#](/creator/twitter::82162291/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::82162291/c:line/m:posts_active.svg)

- X Week XX -XX%
- X Month XXX -XX%
- X Months XXX +4%
- X Year XXX +81%

### Followers: XXXXXX [#](/creator/twitter::82162291/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::82162291/c:line/m:followers.svg)

- X Week XXXXXX +1.60%
- X Month XXXXXX +2.60%
- X Months XXXXXX +11%
- X Year XXXXXX +17%

### CreatorRank: XXXXXXX [#](/creator/twitter::82162291/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::82162291/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  [finance](/list/finance)  [technology brands](/list/technology-brands) 

**Social topic influence**
[$wve](/topic/$wve) #9, [$capr](/topic/$capr) #27, [$srpt](/topic/$srpt) #11, [$cytk](/topic/$cytk), [weight loss](/topic/weight-loss) #583, [$4516t](/topic/$4516t) #1, [$mlys](/topic/$mlys), [$nktr](/topic/$nktr), [$tngx](/topic/$tngx), [$rvmd](/topic/$rvmd)

**Top accounts mentioned or mentioned by**
[@bananaoncology](/creator/undefined) [@sportsbios](/creator/undefined) [@biohazard3737](/creator/undefined) [@houndcl](/creator/undefined) [@jialiangliang](/creator/undefined) [@amaymd](/creator/undefined) [@bigpharmaguy](/creator/undefined) [@jacobplieth](/creator/undefined) [@given2tweet](/creator/undefined) [@monacobiotech](/creator/undefined) [@semodough](/creator/undefined) [@plainyogurt21](/creator/undefined) [@sanctuarybio](/creator/undefined) [@jfais20](/creator/undefined) [@financebully](/creator/undefined) [@aaronrosenblum5](/creator/undefined) [@adamfeuerstein](/creator/undefined) [@johnbresnahan](/creator/undefined) [@masterlongevity](/creator/undefined) [@jeromeleonard5](/creator/undefined)

**Top assets mentioned**
[Wave Life Sciences Ltd. Ordinary Shares (WVE)](/topic/$wve) [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Cytokinetics Inc. (CYTK)](/topic/$cytk) [Mineralys Therapeutics, Inc. Common Stock (MLYS)](/topic/$mlys) [Revolution Medicines, Inc. Common Stock (RVMD)](/topic/$rvmd) [Arrowhead Research Corporation (ARWR)](/topic/$arwr) [Celldex Therapeutics, Inc (CLDX)](/topic/$cldx) [Disc Medicine, Inc. Common Stock (IRON)](/topic/$iron) [Cidara Therapeutics, Inc. (CDTX)](/topic/$cdtx) [Bitcoin Incognito (XBI)](/topic/$xbi) [Janux Therapeutics, Inc. Common Stock (JANX)](/topic/$janx) [Dyne Therapeutics, Inc. Common Stock (DYN)](/topic/$dyn) [Novo-Nordisk (NVO)](/topic/$nvo) [Eli Lilly and Company (LLY)](/topic/$lly) [Hims & Hers Health, Inc. (HIMS)](/topic/$hims) [Pfizer, Inc. (PFE)](/topic/$pfe) [Terns Pharmaceuticals, Inc. Common Stock (TERN)](/topic/$tern) [Kymera Therapeutics, Inc. Common Stock (KYMR)](/topic/$kymr)
### Top Social Posts
Top posts by engagements in the last XX hours

"@RNAiAnalyst @MartinShkreli @MicrobiomDigest $CAPR nothing strange there. Below is a similar plot from $SRPT by definition error bars look identical. Estimates across endpoints are standardized by dividing LSmean and 95%CIs with standard error"  
[X Link](https://x.com/avidresearch/status/1996893916503924888)  2025-12-05T10:46Z 11.7K followers, 2805 engagements


"$WVE definitely has X INHBE valuation built into it. 👇 Would argue its exon XX drug should justify most of its current valuation. They will be submitting WVE-N531 NDA to FDA next year. Vyondys XX from $SRPT and Viltepso from Nippon Shinyaku are X drugs approved for exon XX DMD. Both collectively bring in about $250M-$300M/yr (Viltepso brought in $70.8M in H1 2025). There are no other late stage players. $WVE drug is vastly superior to both of these approved drugs (just look at dystrophin levels) and will be monthly dosing option(vs weekly for X approved drugs)"  
[X Link](https://x.com/avidresearch/status/1997991378895138933)  2025-12-08T11:27Z 11.7K followers, 9626 engagements


"$MLYS $CYTK $NKTR $ABVX attractive M&A candidates"  
[X Link](https://x.com/avidresearch/status/1968365492143530333)  2025-09-17T17:24Z 11.7K followers, 8414 engagements


"$TNGX 1)Competitive mPFS in 2L PDAC . Combo with $RVMD gives em a path fwd in 1L (vs competition) 2) XX% ORR in other histologies (not including PDAC and NSCLC) 3) big NSCLC update coming in 2026 4) Head and Neck ORR=100% (small N=3) and all three PRs are ongoing"  
[X Link](https://x.com/avidresearch/status/1981687260866396422)  2025-10-24T11:40Z 11.7K followers, 21K engagements


"Companies that can/should go up in sympathy since I own them $IRON $NKTR $CYtK $WVE"  
[X Link](https://x.com/avidresearch/status/1989126621287313824)  2025-11-14T00:21Z 11.7K followers, 10.2K engagements


"Agree. $TNGX partnership with $RVMD is highly under appreciated by street. Think that combo could become the gold standard in 1L MTAP del PDAC. Optimistically they said they can start ph3 in 1L by end of next year"  
[X Link](https://x.com/avidresearch/status/1991872466395041825)  2025-11-21T14:12Z 11.7K followers, 3469 engagements


"So $JANX has to just stretch out its dosing intervals"  
[X Link](https://x.com/avidresearch/status/1996770301699674554)  2025-12-05T02:35Z 11.7K followers, 4705 engagements


"$FULC cutting annualized VOC event rate by XX% (assuming no more VOC in few weeks of follow up left). Gene therapy Casgevy led to XX% subjects being VOC free. Pociredir appears to be close to XX% (again assuming the HbF spike leads to no further VOCs among those X subjects). 🔥🔥"  
[X Link](https://x.com/avidresearch/status/1997659096636342400)  2025-12-07T13:26Z 11.7K followers, 4756 engagements


"$DYN increases dystrophin in exon XX to XXXX% at month X. Mktcap $2.8B $WVE can deliver that with no renal adverse event risk (as shown in exon 53)"  
[X Link](https://x.com/avidresearch/status/1997999174223061413)  2025-12-08T11:58Z 11.7K followers, 3170 engagements


"$ARWR (no position)"  
[X Link](https://x.com/avidresearch/status/1993732832720556541)  2025-11-26T17:25Z 11.7K followers, 4002 engagements


"lol. $JSPR $CLDX"  
[X Link](https://x.com/avidresearch/status/1995863756254183760)  2025-12-02T14:32Z 11.7K followers, 2456 engagements


"In serious management hands worth 1/2 of $CLDX"  
[X Link](https://x.com/avidresearch/status/1995893027068387387)  2025-12-02T16:29Z 11.7K followers, 3529 engagements


"$CAPR I have been a skeptic of this name but lets be honest they generated a data set that is stronger than anything $SRPT ever generated"  
[X Link](https://x.com/avidresearch/status/1996261960115995060)  2025-12-03T16:55Z 11.7K followers, 11K engagements


"$CAPR was digging a bit more. They actually have been transparent about the timing of the SAP all along. They cannot change content of what they shipped to the FDA in late September 😀(primary endpoint is what is in that document). There are numerous examples of SAPs for large ph3 being finalized (amendments) 1-2 months before DBlock. Sep XX -"So in terms of the specific analysis plan submission that is imminent. We're planning on submitting that really within the next few days. It's finalized and under final review. So we're looking forward to getting that in." Nov XX Earnings call - "We are"  
[X Link](https://x.com/avidresearch/status/1996920788004250058)  2025-12-05T12:33Z 11.7K followers, 5350 engagements


"Obesity companies can make money regardless of insurance reimbursement. $LLY $NVO have shown the way for next generation obesity drugs"  
[X Link](https://x.com/avidresearch/status/1995486969900487052)  2025-12-01T13:35Z 11.7K followers, 4542 engagements


"@JacobPlieth $CAPR yes on first blush but the fact they met multiple secondary endpoints puts this in a different league than Sarepta. Sarepta didnt even meet primary in any of their trials (secondary is a non starter)"  
[X Link](https://x.com/avidresearch/status/1996267467170042022)  2025-12-03T17:17Z 11.7K followers, 2829 engagements


"$PFE could be looking at plenty of other cardio assets $MLYS (more affordable with $2B peak plus potential) $CYTK"  
[X Link](https://x.com/avidresearch/status/1983871238746341693)  2025-10-30T12:18Z 11.7K followers, 4550 engagements


"Going to be one crazy Monday $gpcr $wve $fulc $tern"  
[X Link](https://x.com/avidresearch/status/1997831683886985404)  2025-12-08T00:52Z 11.7K followers, 5314 engagements


"$WVE new sheriff in obesity town"  
[X Link](https://x.com/avidresearch/status/1998010619300086115)  2025-12-08T12:43Z 11.7K followers, 20.5K engagements


"$WVE this has a perfect profile for a post-GLP weight maintenance setting"  
[X Link](https://x.com/avidresearch/status/1998014386334503313)  2025-12-08T12:58Z 11.7K followers, 1454 engagements


"My view for INHBE $WVE has always been that its a perfect drug for post GLP1 setting. Once a year drug that will help preserve weight loss (no nausea/diarrhea/constipation /muscle loss). Can be direct to consumer drug. A randomized withdrawal study post GLP1 usage can help achieve insurance coverage"  
[X Link](https://x.com/avidresearch/status/1998015554511049032)  2025-12-08T13:03Z 11.7K followers, XXX engagements


"@financebully INHBE just getting started and data will flow continuously over next X months. $ARWR will release its data in X weeks. That study also has a combo with low dose GLP1. $WVE has a more data coming in Q1"  
[X Link](https://x.com/avidresearch/status/1998017854915141984)  2025-12-08T13:12Z 11.7K followers, XXX engagements


"$KYMR 🤯🤯 (no position)"  
[X Link](https://x.com/avidresearch/status/1998050099469885748)  2025-12-08T15:20Z 11.7K followers, 2483 engagements


"GLP1 REBOUND is a REAL problem in REAL world. $WVE"  
[X Link](https://x.com/avidresearch/status/1998206845983625354)  2025-12-09T01:43Z 11.7K followers, 4277 engagements


"$WVE After weight loss from GLP1 as an induction therapy a drug that can minimize fat accumulation and therefore slow weight rebound by a simple annual dosing has a role in maintenance setting. If a randomized withdrawal study (post glp1) is positive that is a whole LOT of weight loss preservation in real world setting"  
[X Link](https://x.com/avidresearch/status/1998207897554067662)  2025-12-09T01:47Z 11.7K followers, 1740 engagements


"@JacobPlieth dont recall seeing a HR that impressive in oncology. Stunning result. "(hazard ratio HR 0.17; XX percent confidence interval CI 0.12-0.23; P0.0001)""  
[X Link](https://x.com/avidresearch/status/1998378560927695057)  2025-12-09T13:05Z 11.7K followers, XXX engagements


"@JacobPlieth I go back and forth on TCEs everyday. Just when i think they peaked as a modality these datasets drop and remind me of how impactful they are across multiple indications"  
[X Link](https://x.com/avidresearch/status/1998379459695780285)  2025-12-09T13:09Z 11.7K followers, XXX engagements


"@meremrtl Yes X% is slower weight loss (as MOa suggests). Potency of this drug will come into play really well post GLP1 when folks switch from calorie deficit diet to high calorie diet (weight rebound). That study is coming and that is a BIG market (better compliance)"  
[X Link](https://x.com/avidresearch/status/1998434849401524713)  2025-12-09T16:49Z 11.7K followers, XXX engagements